|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM174650701 |
| 003 |
DE-627 |
| 005 |
20231223140405.0 |
| 007 |
tu |
| 008 |
231223s2008 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0582.xml
|
| 035 |
|
|
|a (DE-627)NLM174650701
|
| 035 |
|
|
|a (NLM)17964220
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gardulf, A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.02.2008
|
| 500 |
|
|
|a Date Revised 18.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The aims of the present study were to evaluate the health-related quality of life (HRQL) and treatment satisfaction (TS) of adults and children with primary antibody deficiencies (PAD) before and after the introduction of subcutaneous immunoglobulin G (SCIG) self-infusions at home and to identify prognostic factors (demographic/social, medical, patient/parent reported) for HRQL. 85 adults and 21 parents of children with PAD answered the SF-36 (adults), CHQ-PF50 (parents), and the LQI (adults and parents) at baseline and following 10 months of weekly self-administered SCIG infusions at home. The SCIG home therapy was associated with significant improvements in HRQL and TS, particularly in patients who had previously received IVIG therapy in hospital settings. Background factors that were found to be associated with HRQL changes in adults were age, serum IgG levels at month 10, concomitant joint/muscle/skeletal disorders, clinical study location and smoking status
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Multicenter Study
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 700 |
1 |
|
|a Borte, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ochs, H D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nicolay, U
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a Vivaglobin Clinical Study Group
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 126(2008), 1 vom: 15. Jan., Seite 81-8
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:126
|g year:2008
|g number:1
|g day:15
|g month:01
|g pages:81-8
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 126
|j 2008
|e 1
|b 15
|c 01
|h 81-8
|